Lack of evidence for mutations or deletions in the CDKN2A/p16 and CDKN2B/p15 genes of Brazilian neuroblastoma patients

Neuroblastoma, the most common extracranial tumor in childhood, has a wide spectrum of clinical and biological features. The loss of heterozygosity within the 9p21 region has been reported as a prognostic factor. Two tumor suppressor genes located in this region, the CDKN2B/p15 and CDKN2A/p16 (cyclin-dependent kinase inhibitors 2B and 2A, respectively) genes, play a critical role in cell cycle progression and are considered to be targets for tumor inactivation. We analyzed CDKN2B/p15 and CDKN2A/p16 gene alterations in 11 patients, who ranged in age from 4 months to 13 years (male/female ratio was 1.2:1). The most frequent stage of the tumor was stage IV (50%), followed by stages II and III (20%) and stage I (10%). The samples were submitted to the multiplex PCR technique for homozygous deletion analysis and to single-strand conformation polymorphism and nucleotide sequencing for mutation analysis. All exons of both genes were analyzed, but no deletion was detected. One sample exhibited shift mobility specific for exon 2 in the CDKN2B/p15 gene, not confirmed by DNA sequencing. Homozygous deletions and mutations are not involved in the inactivation mechanism of the CDKN2B/p15 and CDKN2A/p16 genes in neuroblastoma; however, these two abnormalities do not exclude other inactivation pathways. Recent evidence has shown that the expression of these genes is altered in this disease. Therefore, other mechanisms of inactivation, such as methylation of promoter region and unproperly function of proteins, may be considered in order to estimate the real contribution of these genes to neuroblastoma genesis or disease progression.

Saved in:
Bibliographic Details
Main Authors: Bassi,C.L., Martelli,L., Cipolotti,R., Scrideli,C.A., Defávery,R., Tone,L.G.
Format: Digital revista
Language:English
Published: Associação Brasileira de Divulgação Científica 2004
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2004001100014
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0100-879X2004001100014
record_format ojs
spelling oai:scielo:S0100-879X20040011000142004-10-28Lack of evidence for mutations or deletions in the CDKN2A/p16 and CDKN2B/p15 genes of Brazilian neuroblastoma patientsBassi,C.L.Martelli,L.Cipolotti,R.Scrideli,C.A.Defávery,R.Tone,L.G. p15 gene p16 gene Deletion Mutation Neuroblastoma Neuroblastoma, the most common extracranial tumor in childhood, has a wide spectrum of clinical and biological features. The loss of heterozygosity within the 9p21 region has been reported as a prognostic factor. Two tumor suppressor genes located in this region, the CDKN2B/p15 and CDKN2A/p16 (cyclin-dependent kinase inhibitors 2B and 2A, respectively) genes, play a critical role in cell cycle progression and are considered to be targets for tumor inactivation. We analyzed CDKN2B/p15 and CDKN2A/p16 gene alterations in 11 patients, who ranged in age from 4 months to 13 years (male/female ratio was 1.2:1). The most frequent stage of the tumor was stage IV (50%), followed by stages II and III (20%) and stage I (10%). The samples were submitted to the multiplex PCR technique for homozygous deletion analysis and to single-strand conformation polymorphism and nucleotide sequencing for mutation analysis. All exons of both genes were analyzed, but no deletion was detected. One sample exhibited shift mobility specific for exon 2 in the CDKN2B/p15 gene, not confirmed by DNA sequencing. Homozygous deletions and mutations are not involved in the inactivation mechanism of the CDKN2B/p15 and CDKN2A/p16 genes in neuroblastoma; however, these two abnormalities do not exclude other inactivation pathways. Recent evidence has shown that the expression of these genes is altered in this disease. Therefore, other mechanisms of inactivation, such as methylation of promoter region and unproperly function of proteins, may be considered in order to estimate the real contribution of these genes to neuroblastoma genesis or disease progression.info:eu-repo/semantics/openAccessAssociação Brasileira de Divulgação CientíficaBrazilian Journal of Medical and Biological Research v.37 n.11 20042004-11-01info:eu-repo/semantics/othertext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2004001100014en10.1590/S0100-879X2004001100014
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Bassi,C.L.
Martelli,L.
Cipolotti,R.
Scrideli,C.A.
Defávery,R.
Tone,L.G.
spellingShingle Bassi,C.L.
Martelli,L.
Cipolotti,R.
Scrideli,C.A.
Defávery,R.
Tone,L.G.
Lack of evidence for mutations or deletions in the CDKN2A/p16 and CDKN2B/p15 genes of Brazilian neuroblastoma patients
author_facet Bassi,C.L.
Martelli,L.
Cipolotti,R.
Scrideli,C.A.
Defávery,R.
Tone,L.G.
author_sort Bassi,C.L.
title Lack of evidence for mutations or deletions in the CDKN2A/p16 and CDKN2B/p15 genes of Brazilian neuroblastoma patients
title_short Lack of evidence for mutations or deletions in the CDKN2A/p16 and CDKN2B/p15 genes of Brazilian neuroblastoma patients
title_full Lack of evidence for mutations or deletions in the CDKN2A/p16 and CDKN2B/p15 genes of Brazilian neuroblastoma patients
title_fullStr Lack of evidence for mutations or deletions in the CDKN2A/p16 and CDKN2B/p15 genes of Brazilian neuroblastoma patients
title_full_unstemmed Lack of evidence for mutations or deletions in the CDKN2A/p16 and CDKN2B/p15 genes of Brazilian neuroblastoma patients
title_sort lack of evidence for mutations or deletions in the cdkn2a/p16 and cdkn2b/p15 genes of brazilian neuroblastoma patients
description Neuroblastoma, the most common extracranial tumor in childhood, has a wide spectrum of clinical and biological features. The loss of heterozygosity within the 9p21 region has been reported as a prognostic factor. Two tumor suppressor genes located in this region, the CDKN2B/p15 and CDKN2A/p16 (cyclin-dependent kinase inhibitors 2B and 2A, respectively) genes, play a critical role in cell cycle progression and are considered to be targets for tumor inactivation. We analyzed CDKN2B/p15 and CDKN2A/p16 gene alterations in 11 patients, who ranged in age from 4 months to 13 years (male/female ratio was 1.2:1). The most frequent stage of the tumor was stage IV (50%), followed by stages II and III (20%) and stage I (10%). The samples were submitted to the multiplex PCR technique for homozygous deletion analysis and to single-strand conformation polymorphism and nucleotide sequencing for mutation analysis. All exons of both genes were analyzed, but no deletion was detected. One sample exhibited shift mobility specific for exon 2 in the CDKN2B/p15 gene, not confirmed by DNA sequencing. Homozygous deletions and mutations are not involved in the inactivation mechanism of the CDKN2B/p15 and CDKN2A/p16 genes in neuroblastoma; however, these two abnormalities do not exclude other inactivation pathways. Recent evidence has shown that the expression of these genes is altered in this disease. Therefore, other mechanisms of inactivation, such as methylation of promoter region and unproperly function of proteins, may be considered in order to estimate the real contribution of these genes to neuroblastoma genesis or disease progression.
publisher Associação Brasileira de Divulgação Científica
publishDate 2004
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2004001100014
work_keys_str_mv AT bassicl lackofevidenceformutationsordeletionsinthecdkn2ap16andcdkn2bp15genesofbrazilianneuroblastomapatients
AT martellil lackofevidenceformutationsordeletionsinthecdkn2ap16andcdkn2bp15genesofbrazilianneuroblastomapatients
AT cipolottir lackofevidenceformutationsordeletionsinthecdkn2ap16andcdkn2bp15genesofbrazilianneuroblastomapatients
AT scridelica lackofevidenceformutationsordeletionsinthecdkn2ap16andcdkn2bp15genesofbrazilianneuroblastomapatients
AT defaveryr lackofevidenceformutationsordeletionsinthecdkn2ap16andcdkn2bp15genesofbrazilianneuroblastomapatients
AT tonelg lackofevidenceformutationsordeletionsinthecdkn2ap16andcdkn2bp15genesofbrazilianneuroblastomapatients
_version_ 1756391096832753664